

Research Paper**Seroprevalence of Herpes Simplex Virus Infections
among Pregnant Women attending Antenatal Clinic in
Benin, Nigeria.****ABSTRACT**

Aims: In many countries, genital herpes, which is predominantly caused by HSV-2 in Nigeria, has become a public health problem of such increasing magnitude that national genital herpes control programmes have been instituted.. Advocacy for formulation of such a programme and the types of interventions to be included in the programme in Nigeria will require data on the prevalence of the disease and the associated factors. Moreover, most of the candidate vaccines against HSV-2 tend to fail when administered to HSV-1 infected persons. The utility of such vaccines in Nigeria will depend on the current seroprevalence of HSV-1 infections.

The aim of this study is to assess the seroprevalence of HSV-1 and HSV-2 infections among pregnant women attending antenatal clinic in University of Benin Teaching Hospital (UBTH); and to verify the association between HSV-2 infection and HIV-status, age, parity, level of education and positive history of painful genital ulcers.

Study Design: Cross-sectional study design was adopted.

Place and duration of the study: 264 pregnant women attending antenatal clinic in UBTH were prospectively and consecutively included in the study which took place between December, 2011 and August, 2012.

Methodology: The patients were tested for HSV-1 IgG and IgM; and for HSV-2 IgG and IgM, using ELISA technique. Their HIV statuses were also determined. Data analysis was done using SPSS version 16.

Results: HSV-2 antibodies were present in 44.3% while HSV-1 antibodies were present 96.6% of the participants. Age, HIV-status and marital status were found to be significantly associated with occurrence of HSV-2 antibodies; while parity, level of education and history of painful genital ulcers had no significant association.

Conclusion: Seroprevalence of HSV-1 infection was 96.6% while that of HSV-2 infection was 44.3%. Factors that were significantly associated with occurrence of HSV-2 infection included age, marital status and HIV status.

32

33 *Key words: HSV-1, HSV-2, Seroprevalence, serostatus,*

34 **1.0 INTRODUCTION**

35 Genital herpes is a disease caused by Herpes Simplex Viruses, which are Herpesviruses of
 36 alphaherpesvirinae subfamily. In Nigeria, as in most sub-Saharan African countries, this disease is
 37 predominantly caused by Herpes Simplex Virus type 2 (HSV-2) and has become a public health problem of
 38 such an increasing magnitude that a national genital herpes prevention programme has become urgently
 39 needed for its control [1,2]. It affects an estimate of 356 million (about 16%) persons in the reproductive age
 40 range, worldwide[1].The disease has been described as an insidious and progressive worldwide pandemic;
 41 and different countries are said to be have different grades of the epidemic[1].The epidemiological factors
 42 determining the persistent spread of this disease are similar to those of Human Immunodeficiency Virus
 43 (HIV) infection; and both diseases have become mutually reinforcing epidemics[3,4]. Among countries in
 44 the sub-Saharan region, in which resides the vast majority of people living HIV/AIDS, the prevalence of
 45 genital herpes in females of the reproductive age group has been said to range between 30%-80%[5].

46 The occurrence of genital herpes among pregnant women, though clinically inapparent in most of the
 47 cases, is particularly associated with several problems in the woman and in the offspring[6]. The most
 48 devastating direct impact of maternal genital herpes is the neonatal disease[1,6]. Genital herpes in
 49 pregnancy is associated with definite risks of meningoencephalitis and disseminated herpes in the
 50 neonate[1,7]. Neonatal meningoencephalitis kills about 50% of affected babies and leaves the survivors
 51 with permanent neurologic deficit[7,8]; while disseminated neonatal disease kills close to 90% of the
 52 infected[8,9]. Moreso, congenital anomalies in the newborn can result.[10,11]. The risk of transmission of
 53 this infection from mother to newborn can increase 10-fold if the primary/initial maternal infections were
 54 acquired during the pregnancy, especially in the third trimester [12]. This risk of transmission and the
 55 severity of the neonatal disease has been reported to increase further if the woman is HIV-infected[13]; and
 56 moreso, if the newly infected pregnant woman did not have prior HSV-1 infection[1,13].

57 Genital herpes in pregnancy is also associated with obstetric complications like intrauterine growth
 58 retardation, intrauterine death, prematurity and spontaneous abortion[6,7].

In the clinically apparent maternal primary genital herpes, painful genital ulceration is the commonest presenting feature.[14] In some cases of primary herpes , however, on the disease can potentially lead to a fatal disseminated herpes in the pregnant woman, especially in immunocompromised states.[14]. In addition to the pains due to maternal genital ulcer disease, the psychosocial impact of the disease on family life is enormous[15]. Genital herpes also leads to enhanced transmission of HIV infection, including enhanced maternal-to-fetal HIV transmission[1,15]. Furthermore, every HSV infection is lifelong, despite adequate therapy, and the host is subsequently ever at risk of severe disease, should there be immunodeficiency[14].

It is therefore imperative that definite policy-based control measures need to be put in place to preventively manage genital herpes in pregnancy in any country[2]. Advocacy for formulation of such policy guidelines and the design of the specific interventions require local data on the prevalence of the disease and the associated factors. As the disease is not often detectable clinically, there is recourse to serology for retrospective detection and prevalence studies. Herpes Simplex Virus type 2 (HSV-2) seroprevalence studies provide reliable approximations of genital herpes prevalence in all regions[1]. There's yet no published data on the prevalence in the Nigerian general population, though are prevalence values among commercial sex workers and among sexually transmitted infection clinic attendees.[16,17]. In the absence of general population-based studies, data based on antenatal clinic attendees, as in this study, can be taken as significantly representative of the general population data[1].

So much effort is being made to develop vaccines against HSV-2 and many of the candidate vaccines are ineffective on HSV-1 seropositive persons[4]. The proportion of HSV-1 seronegative persons in Nigeria, as derived from this study, will determine the possible usefulness of the vaccine here. A study done in the 1970's in Nigeria found the HSV-1 prevalence among youths and adults to be 100%[18]. However, recent reports show that adult HSV-1 prevalence values decline as socioeconomic status and environmental hygiene improve[19]. Therefore, data on the current seroprevalence of HSV-1 infections, as well as HSV-2 infections, should be vital to policy planning in Nigeria especially if vaccine-based intervention is in view.

2.0 MATERIALS AND METHODS

2.1 Study area, population and design

Study location was University of Benin Teaching Hospital (UBTH), located in Benin, Edo state capital city of Nigeria. UBTH is a tertiary health care centre that serves as a referral centre in Southern Nigeria. Cross-sectional study design was adopted. Two hundred and sixty-four (264) ante-natal clinic attendees of UBTH were consecutively and prospectively recruited in a study that took place between December, 2011 and August 2012. Informed consent was obtained from the respondents. Data sources were structured interviewer-administered questionnaire, patients case notes and laboratory investigations. The questionnaire was used to elicit sociodemographic and obstetric information; along with information on the occurrence of genital ulcers. Patients' sera were used for HSV-1 IgG, HSV-1 IgM, HSV-2 IgG, HSV-2 IgM, and HIV immunoassays.

2.2 Laboratory Procedures

Blood samples were collected in 5 ml plain vacutainer tubes and allowed to clot and sera separated by centrifugation at room temperature. Storage was in cryovials at -20°C .

2.2.1 HSV-1 and HSV-2 IgG assay procedure: This utilized Enzyme Linked Immunosorbent Assay (ELISA) kit by Dia. Pro. Diagnostic Bioprobes Milano – Italy. This is a glycoprotein G-based enzyme-linked immunosorbent assay (ELISA) technique and test result was qualitative.

All specimens and kit reagents were brought to room temperature and gently mixed. The wash buffer was prepared by diluting the wash concentrate 1 in 10. Dilutions of the test serum, controls and calibrator were added into the appropriate wells which were pre-coated with HSV-1 and 2 antigens. Antibodies in the patient's sera should bind to the antigens to form immune complexes. Tetramethylbenzidine/Hydrogen peroxide (chromogenic substrate) was added to produce coloured reaction which intensity depends on the amount of antibody in the complex. The assay was blanked using the sample diluents. The well contents were thoroughly mixed and incubated for 30 minutes at room temperature. All liquid was then removed from all wells and washing was done three times with wash buffer. Polyclonal anti-IgG-Horseradish peroxidase conjugate was then added to each well and incubated for 30 minutes at room temperature in order to detect any such complexes. This was followed by another

triple-wash step. Then a chromogenic substrate was added to each well and another incubation for 30 minutes at room temperature was done. 2N HCl stop solution was then added. The intensity of the colour (OD) that develops was measured using a spectrophotometer with a 450nm measurement filter. The absorbance should be proportional to the concentration of the HSV antibodies. With each set of tests were 3 sets of calibrators (CAL1a and CAL1b; CAL2a and CAL2b; and CAL6) of concentrations 0 U/ml, 5 U/ml and 100 U/ml. The calibrators and controls are utilized in internal quality control and in qualitative interpretation of the assay. Each assay was validated if the mean absorbance (OD) of CAL1 is less than 0.150; the mean absorbance of CAL2 is more than $0.100 + \text{CAL1 OD value}$; and the CAL6 OD value is more than 1.000. Once the assay was validated, sample OD value higher than mean CAL2 OD value is taken as HSV IgG positive; while sample results with lower O.D values are HSV IgG negative.

2.2.2 HSV-1 and HSV-2 IgM assay procedure: The kit used was Dia. Pro. Diagnostic Bioprobes Milano – Italy.

To the well surfaces, which contains pre-coated monoclonal antibodies against human IgM, were added 100µl of diluted test sera. 100µl of positive controls, negative controls and calibrator were dispensed to the appropriate wells. One blank well was set as background control. Incubation was done at 37°C for 60 minutes. Any IgM present in the samples should have bound to the wells. The next step is the addition of 100µl of HSV antigen/antibody immunocomplex ((HSV-1 or HSV -2 specific antigens which has been previously mixed with HSV-specific antibody that is conjugated with horse-radish peroxidase enzyme) to each sample well, controls and calibrator, followed by a thorough mixing. No enzyme conjugate is added to the blank well. Then follows another incubation at 37°C for 60 minutes. The well is washed again. Then, the chromogen/substrate (tetramethylbenzidine/hydrogen peroxide) is added to each well, including the blank. The well contents are mixed gently and incubated at room temperature for 20 minutes. 100µl of Stop Solution (sulphuric acid) is added to each well. The absorbance of all samples (OD) is read at 450 nm.

Result is qualitative. Cut off value (Co) of the assay is calculated using the formula: Cut Off (Co)

= Negative control + 0.250. The ratio of the test OD and cut-off value (S/Co) is calculated for all the samples and calibrator.

The test is validated if the mean OD of the negative control is less than 0.200; if the S/Co of the calibrator is more than 1.2; and if the positive control OD is more than 1.000

Once the assay is validated, a sample with S/Co ratio that is more than 1.2 is HSV IgM-positive.

A sample with S/Co ratio that is between 1.0 and 1.2 is equivocal; while a sample with S/Co result of less than 1.0 is negative.

2.2.3 HIV immunoassay procedure: The HIV statuses of the respondents were previously determined using Determine ® HIV ½ by Inverness Medical Innovations South Africa; and HIV 1 & 2 STAT PAK Assay kit by CHEMBIO Diagnostic system, INC, New York, USA.

Each batch of tests ran with both positive and negative controls and results were qualitative.

2.3 DATA ANALYSIS

Data collected was analyzed using the SPSS version 16 computer software. Fishers exact was used to test associations. Statistical significance was ascribed based on P values < 0.05.

3.0 RESULTS and DISCUSSION

The ages of the 264 included antenatal clinic attendees ranged from 18 years to 44 years. Their mean age was 30.6 ± 5.1 years. While majority (70.5%) of the sample population were between 26 and 35 years of age, age groups 15-20 and 41-50 were in the minority (represented by 1.1% and 2.3% of the respondents). The 46 -50 years age group was not represented.(TABLE 1)

Most (85.3%) of the participants were married. While 7.9% were single, 3.4% each were either widows or divorcees. (TABLE 1) Almost all the participants (99.6%) were Christians, only one (0.4%) of them was a moslem. No other religion was represented in the study population.(TABLE 1)

93.6% of the participants completed secondary education, as 75% of them were educated above secondary level and 18.6% stopped at secondary level of education. (TABLE 1)

TABLE 1: GENERAL CHARACTERISTICS OF RESPONDENTS

CHARACTERISTICS	FREQUENCY	PERCENT (%)
AGE GROUP (YEARS)		
15-20	3	1.1
21-25	36	13.6
26-30	96	36.4
31-35	90	34.1
36-40	33	12.5
41-45	6	2.3
RELIGIONS		
CHRISTIANITY	263	99.6
ISLAM	1	0.4
MARITAL STATUSES		
MARRIED	225	85.3
SINGLE	21	7.9
DIVORCED	9	3.4
WIDOWED	9	3.4
LEVELS OF EDUCATION		
GRADUATE AND ABOVE	81	30.7
POST-SECONDARY	117	44.3
SECONDARY COMPLETED	49	18.6
SECONDARY UNCOMPLETED	5	1.9
PRIMARY COMPLETED	10	3.8
PRIMARY UNCOMPLETED	2	0.8
HIV STATUS		
POSITIVE	32	12.1
NEGATIVE	232	87.9

Most of the participants were recruited either in their second (39.8%) or in their third (45.5%) trimesters of pregnancy; while 14.7% were seen in their first trimesters.

Most (43.6%) of the respondents were nulliparae. Twenty-eight percent (28%) of them were primiparae; 27.6% were multi-parae, while only two (0.8%) of them were grand multiparae.(TABLE 2)

TABLE 2: OBSTETRIC CHARACTERISTICS OF RESPONDENTS

CHARACTERISTICS	FREQUENCY	PERCENT
GESTATIONAL AGES		
1 ST TRIMESTER	39	14.7
2 ND TRIMESTER	105	39.8
3 RD TRIMESTER	120	45.5
PARITY		
NULLIPARA	115	43.6
PRIMIPARA	74	28.0
PARA-2	49	18.6
PARA-3	16	6.0
PARA-4	8	3.0
PARA-5 OR MORE	2	0.8

HSV-2 antibodies were present in 117 of the 264 respondents, giving an HSV-2 seroprevalence of 44.3%. (TABLE 3)

HSV-1 antibodies were present in 255 of the 264 respondents, giving an HSV-1-seroprevalence of 96.6%. (TABLE 3)

TABLE 3: PREVALENCE OF HSV-2 AND HSV-1 ANTIBODIES AMONG PARTICIPANTS

HSV TYPE	ANTIBODY PRESENT(%)	ANTIBODY ABSENT (%)	NUMBER TESTED (%)
HSV-1	255 (96.6)	9 (3.4)	264 (100)
HSV-2	117 (44.3)	147 (55.7)	264 (100)

All the HSV-1 antibodies were of IgG biotype (Table 4)

TABLE 4: PREVALENCE OF HSV-1 ANTIBODY BIOTYPES

HSV TYPE (Antibody Biotype/s)	NUMBER Antibody Biotype/s Present	Percent	NUMBER TESTED
HSV-1 IgG only	255	96.6%	264
HSV-1 IgG +IgM	0	0%	264
HSV-1 IgM only	0	0%	264

Most (110) of the 117 HSV-2 sero-positive participants had IgG biotype only; 3 participants had both IgG and IgM biotypes; while 4 had only IgM biotypes. A total of 7 participants (2.6%) had IgM biotypes (Table 5).

TABLE 5: PREVALENCE OF HSV-2 ANTIBODY BIOTYPES

HSV TYPE (Antibody Biotype/s)	NUMBER Antibody Biotype/s Present	Percent	NUMBER TESTED
HSV-2 IgG only	110	41.7	264
HSV-2 IgG + IgM	3	1.1	264
HSV-2 IgM only	4	1.5	264

The prevalence of HSV-2 antibodies was significantly higher among respondents of higher age groups than among those of lower age groups (Table 6)

The prevalence of HSV -2 antibodies was generally lower among participants who were educated beyond secondary level than among those who were less educated. However, the difference was not significant. ($p = .145$) (TABLE 6)

There was statistically significant difference between the prevalence of HSV-2 infection

238
 239 among the married respondents and the various unmarried counterparts. ($p = .031$) (TABLE 6)
 240 Parity was not found to be significantly associated with the occurrence of HSV-2 antibodies. ($p =$
 241
 242 $.144$) (TABLE 6)

243 The prevalence of HSV-2 antibodies among the HIV-infected was significantly higher than that
 244
 245 of the HIV-uninfected. ($p = .022$) (Table 6).

246 The prevalence of HSV-2 antibodies was higher among those with negative history of painful
 247
 248 genital ulcers than among those with positive history. There was no significant association of
 249
 250 history of painful genital ulcers with occurrence of HSV-2 antibodies.

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

TABLE 6: HSV-2 SEROSTATUS AND PARTICIPANT CHARACTERISTICS

CHARACTERISTICS	HSV-2 ANTIBODY POSITIVE(%)	HSV-2 ANTIBODY NEGATIVE(%)	TOTAL(%)	P-VALUE
AGE GROUPS				
15-20	2 (66.7)	1(33.3)	3 (1.1)	.04
21-25	11(30.6)	25 (69.4)	36 (13.6)	
26-30	36 (37.5)	60 (62.5)	96 (36.4)	
31-35	42 (46.7)	48 (53.3)	90 (34.1)	
36-40	23 (69.7)	10 (30.3)	33 (12.5)	
41-45	3 (50)	3 (50)	6 (2.3)	
LEVEL OF EDUCATION				
Graduate and above	33 (40.7)	48 (59.3)	81(30.7)	.145
Post-secondary	50 (42.7)	67 (57.3)	117 (44.3)	
Secondary completed	23 (46)	27 (54)	50 (18.9)	
Secondary uncompleted	5 (100)	0 (0)	5 (1.9)	
Primary completed	6 (60)	4 (40)	10 (3.8)	
Primary uncompleted	0 (0)	1(100)	1 (0.4)	
MARITAL STATUS				
MARRIED	94 (41.8)	131 (58.2)	225 (85.3)	.031
SINGLE	10 (47.6)	11(52.4)	21 (7.9)	
DIVORCED	7 (77.8)	2 (22.2)	9 (3.4)	
WIDOWED	6 (66.7)	3 (33.3)	9 (3.4)	
PARITY				
NULLIPARA	42(36.5)	73 (43.5)	115 (43.6)	.144
PRIMIPARA	37(50)	37(50)	74 (28.0)	
PARA-2	22 (44.9)	27 (45.1)	49 (18.6)	
PARA-3	10 (62.5)	6 (37.5)	16 (6.0)	
PARA-4	6 (75.0)	2 (25.0)	8 (3.0)	
PARA-5 OR MORE	0(0.0)	2 (100.0)	2 (0.8)	
HIV STATUS				
POSITIVE	21(65.6)	11(34.4)	32 (12.1)	.022
NEGATIVE	96 (41.4)	136 (58.6)	232 (87.9)	
HISTORY OF PAINFUL GENITAL ULCERS				
POSITIVE	9 (36)	16 (64)	25 (9.5)	.399
NEGATIVE	108 (45.2)	131(54.8)	239 (90.5)	

Only 9 of the participants (3.4%) were HSV-1 negative. HSV-1 antibodies were 100% prevalent among the younger age groups.(Table 7)

TABLE 7: PRESENCE OF HSV-1 ANTIBODIES AMONG THE VARIOUS AGE GROUPS

		PRESENCE OF HSV-1 ANTIBODIES		
		Positive(%)	Negative(%)	TOTAL(%)
AGE GROUPINGS OF RESPONDENTS (YEARS)	15-20	3(100)	0(0)	3(1.1)
	21-25	36(100)	0(0)	36(13.6)
	26-30	93(96.9)	3(3.1)	96(36.4)
	31-35	87(96.7)	3(93.3)	90(34.1)
	36-40	30(90.9)	3(0.1%)	33(12.5)
	41-45	6(100)	0(0)	6(2.3)
TOTAL		255	9	264

DISCUSSION

In this study, the seroprevalence of HSV-2 infection was found to be 44.3%. In accordance with the observation that seroprevalence values among pregnant sub-populations correlates consistently with those of the general population, the result of this study can be presumed to approximate seroprevalence of HSV-2 infection in Nigeria [1]. This HSV-2 seroprevalence value, by extension, approximates genital herpes prevalence, since occurrence of HSV-1 genital herpes has been shown to be negligible in this region[2]. This prevalence value is high and no other published report on the seroprevalence of HSV-2 infection among the pregnant population in Nigeria was found. Lower HSV-2 seroprevalence findings of 20.7%, and 26% were, however, found among pregnant women in Tanzania and Senegal, all of sub-Saharan Africa region.[20,21] When compared to the seroprevalence in other value in this study is much higher than the HSV-2 seroprevalence of 7.5% and 21% reported among pregnant women in India and USA respectively.[22,23]

The mutual re-inforcement of transmission efficiency exhibited by HIV-infection and HSV-2 infection could be contributory to this high prevalence in Nigeria. Moreover, the infection was significantly more prevalent among the HIV-infected participants than among the HIV-uninfected counterparts, in this study. Detailed study of the epidemiology of HSV-2 infection in the Nigerian locality is necessary to enable accurate definition of strategies, targets and possible mode of integration of genital herpes and HIV-infection control programmes. The myriad of potential, and largely unexplored, problems associated with high prevalence of genital herpes in Nigeria demands that the Nigerian Federal Ministry of Health exercise greater proactivity in the her response to this infection.[1,2] The response should involve ascertainment of the burden, risk factors, and deterrent of the infection using wider multicentred population survey. The challenges being faced in the control of HIV infection may be strongly related to the silent but very active genital herpes pandemic. Therefore national response to the HIV scourge may not be adequate until there is an appropriate specific response to HSV-2 infection. Due to the perculiar problems associated with genital herpes in pregnancy, pregnant women must be included, among other control targets. Such programmes should involve several interventions ranging from specific health education to testing of target populations. Consequent on limited resources, testing all pregnant women for HSV-2 infection may not be feasible. In this study, significant associations between HSV-2 infections and marital status, age and HIV-status were found. These three associated characteristics could form the basis for selection of pregnant women for screening tests. Specific interventions could be designed for the tested pregnant women based on their sero-status. For instance HSV-2 sero-negative women could benefit from sexual health education; while HSV-2 IgM seropositive ones could benefit from close monitoring of the pregnancy, especially, during the peurperium, when the chance of maternal-to-child transmission is high. Such primary infections occurring during pregnancy (especially late pregnancy) may require elective caesarean section and/or presumptive treatment of the neonate for neonatal herpes[24,25]. In this study, 2.7% of the study population had IgM biotype of HSV-2 antibodies, indicating that HSV-2 transmission is on-going in Nigerian communities. The outcome of these pregnancies that are associated with IgM HSV-2 antibodies in this environment require ascertaining.

In this study, there was no significant association between HSV seroprevalence and positive history of genital ulcers. The significance of this finding may be hampered by the non-specific nature of the pathogenesis of genital ulcers. Ulcers in the genital area could be caused by microbes other than HSV. These include other sexually transmitted infections like granuoma inguinale, syphilis, soft chancre, lymphogranuloma inguinale; non-sexually transmitted infections like herpes zoster, furuncles, scabies, pediculosis, erythema multiforme, and trauma. Moreover, only a minority of the participants could recall having had painful genital ulcers, which points to the reduced importance of this factor in the Nigerian environment.

The seroporevalence of HSV-1, in this study, was found to be 96.6%. This value is only 3.4% lower than that the 100% seroprevalence found in a study done in Western Nigeria about 40 years ago.¹⁸ Less HSV-1 seroprevalence value of 57.7% was reported from USA; and a reduction of 6.9% occurred between

1999 and 2004[26]. These reduction was driven by improvement in personal and environmental hygiene.[26] The less significant reduction in HV-1 seroprevalence in Nigeria may be due to the inconsistent environmental sanitation improvements; as our urban areas are rapidly turning to slums.

The HSV-1 seroprevalence result in this study conforms to the finding that HSV-1 seroprevalence still tends to be high as from age five and above, in sub-Saharan African countries; and this is due to early acquisition of the infection in childhood by non-sexual means[2]. Consequent on this, HSV-1 seroprevalence among adolescents and young adults in these countries tend to be more than 90%; and this has been observed in Eritrea, Uganda, and Central African Republic [27]. The implications of this high HSV-1 seroprevalence are that the rate of childhood HSV-1 infection is still very high in our communities. The early acquisition of HSV-1 infection is attested to by the fact all those in the younger age groups had the infection; and all the HSV-1 infected participants had IgG biotype. The protective effect of HSV-1 antibodies implies that the incidence of HSV-1 genital herpes will remain negligible[2].

The high prevalence of HSV-2 infection in the presence of near 100% HSV-1 seroprevalence confirms that the protective effect of HSV-1 antibodies on HSV-2 infection is not complete. The extent of HSV-1-mediated protection of the Nigerian population (especially the pregnant) from the various complications of HSV-2 infection also requires ascertaining.

Since there is a minority (3.4%) of the population that are HSV-1 seronegative, this sub-population of pregnant women and their unborn babies may require specific protection from primary HSV-2 infection and the several severe obstetric complications.

If the fight against HIV must be won, HSV-2 infection must be controlled. HSV-2 vaccine development efforts should therefore be sustained. Many of the candidate HSV-2 vaccines have been found to be rendered ineffective by HSV-1 antibodies[28]. It seems instructive, from the findings of this study that HSV-2 vaccine candidates should be designed specifically for sub-Saharan Africa where the HSV-1 seroprevalence is high.

4.0 CONCLUSIONS

The seroprevalence of HSV-2 infections among pregnant women attending antenatal clinic in UBTH was found to be 44.3%. The factors that were found to be significantly associated with occurrence of HSV-2 infection were age, marital status and HIV-status. HSV-1 seroprevalence was found to be 96.6%

ETHICAL CONSIDERATIONS:

Approval was sought and obtained from the Health Research Ethics Committee of University of Benin Teaching Hospital for this research work. Informed written consent of all the included patients were obtained.

COMPETING INTERESTS

This was a self-sponsored project. No competing interests exist.

REFERENCES

1. Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. *Bull World Health Organ* 2008[cited 2011 12 11; 86(10): 737-816. Available from: [URL:http://www.who.int/bulletin/volumes/86/10/07-046128/en/](http://www.who.int/bulletin/volumes/86/10/07-046128/en/)
2. Corey L, Handsfield HH. Genital Herpes and public health: addressing a global problem. *JAMA* 2000[cited 2011 02 14]; **283**: 791-794. Available from: [URL:www.ncbi.nlm.nih.gov/pubmed/10683059](http://www.ncbi.nlm.nih.gov/pubmed/10683059)
3. Initiative for vaccine research (IVR). Sexually transmitted diseases: Herpes Simplex Virus type 2. World Health Organization; 2011[cited 04 07 11]. Available from: http://www.who.int/vaccine_research/diseases/soa_std/en/index3.html
4. Adult Antiretroviral Treatment Protocol. version 2.0 Protocol 08.04.09. President and Fellows of Havard College, Harvard School of public health; 2009.
5. Weiss H. Epidemiology of herpes simplex virus 2 infection in the developing world. *Herpes* 2004[cited 2011 04 02];**11**(1): 24-34.Available from: URL: <http://www.ihmf.com/journal/download/11Weiss%2824A%29sup124A.pdf>
6. Sandhaus S. Genital herpes in pregnant and non-pregnant women. *Nurse Pract.* 2001[cited 2011 01 13];**26**(4):15-6, 21-22, 25-27.Available from: URL:http://findarticles.com/p/articles/mi_qa3958/is_200104/ai_n8946495/
7. Corey L. Herpes simplex viruses. In : Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL.(editors). *Harrison's principles of internal medicine*, 16th ed. New York: McGraw-Hill; 2005. p. 1100 – 1106.

8. Corey L, Tying S, Sacks S, Warren T, Beutner K, Patel R *et al*. Once Daily Valacyclovir Reduces Transmission of Genital Herpes. Presented at 42nd ICAAC, San Diego, California, 2002. Available from: URL:www.ncbi.nlm.nih.gov/pubmed/14702423
9. Duran N. Serological Evaluation of HSV-1 and HSV-2 Infection In Pregnancy. *Turk J Med Sci* 2004[cited 2011 02 12]; **34**: 97-101. Available from: URL: <http://journals.tubitak.gov.tr/medical/issues/sag-04-34-2/sag-34-2-4-0306-7.pdf>.
10. Surpam RB, Kamlakar UP, Khadse RK, Qazi MS, Jalgaonkar SV. Serological study for TORCH infections in women with bad obstetric history. *J Obstet Gynecol India* 2006; **56**(1): 41-43.
11. Mahalakshmi B, Therese KL, Devipriya U, Pushpalatha V, Margarita S & Madhavan HN. Infectious aetiology of congenital cataract based on torches screening in a tertiary eye hospital in Chennai, Tamil Nadu, India. *Indian J Med Res* 2010; **131**:559-564.
12. Jerome KR, Morrow RA. Herpes simplex viruses and Herpes B virus. In: Murray PR, editor. Manual of Clinical microbiology, volumell. 9th edition. Washington: ASM; 2007. p. 1523-1536.
13. Chen KT, Segú M, Lumey LH, Kuhn L, Carter RJ, Bulterys M, *et al*. Genital herpes simplex virus infection and perinatal transmission of human immunodeficiency virus. *Obstet Gynecol*. 2005; **106** (6):1341-1348. Available from: URL:<http://www.ncbi.nlm.nih.gov/pubmed/16319261>
14. Brooks GF, Butel JF, Morse SA. Herpesviruses. In: Jawetz, Melnick and Adelberg's Medical Microbiology. 25th edition. USA: McGraw-Hill Companies, Inc.; 2010. p. 433 – 455.
15. Handsfield HH. Public health strategies to prevent genital herpes: where do we stand? *Curr Infect Dis Rep* 2000[cited 2011 04 02]; **2**: 25-30. Available from: URL:<http://www.ncbi.nlm.nih.gov/pubmed/11095834>

16. Agabi YA, Banwat EB, Mawak JD, Lar PM, Dashe N, Dashen MM, *et al.* Seroprevalence of herpes simplex virus type-2 among patients attending the Sexually Transmitted Infections Clinic in Jos, Nigeria *J Infect Dev Ctries* 2010; 4(9):572-575.
<http://jidc.org/index.php/journal/article/viewDownloadInterstitial/21045370/439>
17. Dada AJ, Ajayi AO, Diamondstone L. A sero-survey of *Haemophilis ducreyi*, Syphilis, and Herpes simplex virus type-2 and their association with HIV among sex workers in Lagos, Nigeria. *Sex Transm Dis* 1998[cited 2011 04 01]; **25**: 237–42.Available from:URL: <http://www.ncbi.nlm.nih.gov/pubmed/9587174>
18. Sogbetun AO, Montefiore D, and Anong CN. Herpesvirus hominis antibodies among children and young adults in Ibadan. *British Journal of Venereal Diseases*, 1979[cited 2011 03 15]; **55**: 4447. Available from: URL: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1045580/pdf/brjvendis00031-0051.pdf>
19. Malkin JE. Epidemiology of genital herpes simplex virus infection in developed countries. *Herpes*. 2004[cited 2011 12 01] ; 11(1): 2A-23A.Available from: URL: <http://www.ihmf.com/journal/download/11Malkin%282A%29sup12A.pdf>
20. Yahya-Malima KI, Evien-Olsen B, Matee MI, Fylkenes K and Haans L. HIV-1, HSV-2 and syphilis among pregnant women in a rural area of Tanzania: prevalence and risk factors. *BMC infect Dis* 2008[cited 2011 12 16]; **8**:75. Doi: 10.1186/1471- 2334-8-75.
21. Diawara S, Kane CT, Legoff J, Gaye AG, Mboup S. Low seroprevalence of Herpes simplex virus type 2 among pregnant women in Senegal. *International J of STD and AIDS* 2008 [cited 2012 Jan 12]; **19**(3):159-160.Available from: URL:<http://www.urbanreproductivehealth.org/publications/low-seroprevalence-herpes-simplex-virus-type-2-among-pregnant-women-senegal>.
22. Rathore S, Jamwal A, Gupta V. Herpes Simplex Virus type 2: Seroprevalence in antenatal women. *Indian J Sex Transm Dis* [serial online] 2010 [cited 2012 Jun 29]; 31: 11-15. doi: 10.4103/0253.7184.68994)
23. Center for Disease Control and Prevention. National Health and Nutrition Examination Survey (NHANES); Morbidity Mortality Weekly Report; 2010[cited 2012 Jan 11]; **59** (15): 456-459.) <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5915a3.htm>.)
24. New Zealand Herpes Foundation. Guidelines for the Management of Genital Herpes in

New Zealand. 9th edition. Viral Sexually Transmitted Infection Education Foundation.

2009[cited 2011 03 14]. Available from: URL:

http://www.herpex.org.nz/pdfs/NZHF%20Guidelines%202009_FA_updated.pdf

25. Money D, Steben M; Society of Obstetricians and Gynaecologists of Canada. SOGC clinical practice guidelines: Guidelines for the management of herpes simplex virus in pregnancy. *Int J Gynaecol Obstet*. 2009 [cited 2011 04 12]; **104**(2):167-71. Available from: URL: <http://www.ncbi.nlm.nih.gov/pubmed/19241496>
26. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, et al. Trends in Herpes Simplex Virus Type 1 and Type 2 Seroprevalence in the United States *JAMA*. 2006; 296 (8):964-973. doi:10.1001/jama.296.8.964
27. Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. *J Infect Dis* 2002[cited 2011 02 14]; 186: S3-28 doi: [10.1086/343739](https://doi.org/10.1086/343739).
28. Stanberry LR, Spruance SL, Cunningham AL,. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. *N Engl J Med*. 2002;347:1654-1661.